Methicillin-resistant Staphylococcus aureus (MRSA) infections
Methicillin-resistant Staphylococcus aureus (MRSA) infections are caused by a strain of Staphylococcus aureus that has developed resistance to common antibiotics, making them challenging to treat. MRSA can enter the body through breaks in the skin from injuries, surgeries, or injections, and can spread throughout the body, potentially leading to severe complications. Symptoms often include fever, pain, redness, swelling, and pus formation at the infection site. While MRSA is commonly associated with skin infections, it can also affect bones, blood, and various organs, leading to conditions such as osteomyelitis and bacterial endocarditis.
Treatment typically involves specific antibiotics known to be effective against MRSA, such as vancomycin and linezolid, often administered intravenously for severe cases. Surgical intervention may be necessary to remove infected tissue or drain abscesses. The rise of MRSA has been linked to its rapid adaptation to antibiotic use, initially observed in healthcare settings but now increasingly present in communities. Public health measures emphasize proper hygiene, prompt treatment of wounds, and responsible antibiotic use to help mitigate the spread of MRSA infections. Continued research into new antibiotics is vital to enhance treatment options for MRSA-related illnesses.
Methicillin-resistant Staphylococcus aureus (MRSA) infections
ALSO KNOWN AS: Methicillin-resistant staph infections
ANATOMY OR SYSTEM AFFECTED: Blood, blood vessels, bones, circulatory system, feet, hands, heart, joints, kidneys, legs, liver, muscles, musculoskeletal system, nose, respiratory system, skin, spine, spleen
DEFINITION: An infection caused by a virulent and destructive bacterium that is resistant to common antibiotics and difficult to treat; may be localized to one area of the body or may become systemic (spread throughout the body)
CAUSES: Bacteria entering through break in skin from trauma, surgery, injection; point of entry may be unidentifiable
SYMPTOMS: Fever, pain, redness, swelling, pus if localized
DURATION: days to weeks; can be fatal if systemic or untreated
TREATMENTS: Antibiotics, surgery
Causes and Symptoms
Staphylococcus aureus is a bacterium commonly found on skin, especially in the nose, axilla (underarm), groin, and rectal areas. Methicillin resistance is the genetically acquired ability of some strains to withstand exposure to a class of antibiotics designed to treat staphylococci. Methicillin-resistant Staphylococcus aureus (MRSA) infections occur when a visible or microscopic break in the skin allows these bacterial organisms to enter the body. Such points of entry may be the result of injury, such as an abrasion sustained wrestling or playing football, or surgical, as in a cesarean section or a joint replacement. Needles used to inject medication or illicit drugs can also introduce these bacteria. Sometimes the source is as innocuous as a hair follicle. Occasionally the source of a bloodstream infection is never identified.
Many strains of MRSA are virulent and destructive. Infections are characterized by fever and pain as well as redness and swelling at the site. Pus may drain from the area or may build up as an abscess within infected tissue. MRSA may be invasive, meaning that it spreads deep into tissues and into the bloodstream and travels through the body infecting other sites. The most common site of infection is the skin where MRSA may cause cellulitis (infection of the skin layers), folliculitis (infection of hair follicles), or boils (abscesses complicating folliculitis). It is a common cause of foot and leg infections in patients with diabetes. Osteomyelitis (bone infection) can occur by direct invasion from an overlying skin infection or through trauma (fracture or foreign body such as shrapnel). When bacteria enter the bloodstream they may find a focus in any organ or tissue and infect that area, sometimes even forming abscesses in these secondary sites. The spine, spleen, and kidneys are common secondary sites. Bacterial endocarditis, or infection of the heart valves and linings, is a particularly dangerous form of MRSA infection and is very difficult to treat. MRSA infections can complicate surgical procedures, causing infection of the incision and sometimes invading deeper tissues or spreading systemically. MRSA infection of surgically placed foreign bodies (artificial joints, bone plates and pins, heart valves) sometimes occurs. MRSA can occur in hospitalized patients who require respirators and is a rare but sometimes fatal complication of influenza.
Treatment and Therapy
Treatment of MRSA infections is challenging both because of the organism’s resistance to antibiotics and because of its aggressive and persistent nature. When possible, laboratory testing of the infecting organism can help guide the selection of antibiotics most likely to be effective. Specimens from the infected site (pus, infected tissue, blood) can be cultured for bacterial growth and the bacteria subjected to testing for susceptibility to a variety of antibiotics. Antibiotics that are shown in the laboratory to kill or inhibit growth of the cultured bacteria are the ones most likely to be effective in treating the infection.
The antibiotics most commonly used for treating MRSA infections are vancomycin, linezolid, daptomycin, quinupristin/dalfopristin, clindamycin, and various forms of sulfa drugs and tetracyclines. Intravenous (IV) treatment is necessary for severe infections. Some infections such as bacterial endocarditis and osteomyelitis require antibiotic treatment for six weeks or more, and relapse is not unusual. Surgical debridement to remove diseased or dead tissue or surgical drainage of an abscess may be necessary in addition to antibiotics. MRSA infection involving a foreign body (for example, a prosthetic joint) is particularly difficult to eradicate; removal of the foreign body is often recommended in addition to antibiotics.
Perspective and Prospects
Since the discovery of microorganisms as a cause of disease, Staphylococcus aureus, a common inhabitant of normal skin, has been shown capable of causing severe, life-threatening infection under some conditions. The introduction of antibiotics proved it able to adapt rapidly through mutation, as some strains became resistant first to penicillin and later to the semi-synthetic penicillins (such as methicillin) designed to treat penicillin-resistant staphylococci. Initially, these antibiotic-resistant strains were found almost entirely in hospitals and nursing homes where exposure to antibiotics and evolutionary pressure favored their development. Since the 1990s, MRSA has become widespread outside these settings. Some of these “community-acquired” strains, or CA-MRSA (as distinguished from hospital-acquired or HA-MRSA), have caused severe infections and even death in young, otherwise healthy people who became infected through minor sports injuries or following influenza. Public health authorities have instituted more stringent guidelines for cleaning athletic equipment, requiring athletes to immediate shower after practices and competitions, excluding infected athletes from participation, covering open wounds with bandages, and so on. Education and public awareness of appropriate hygiene and infection control measures are important in reducing the spread of the infection through communities. Efforts to reduce unnecessary or inappropriate antibiotic use (overprescription or premature discontinuation of a prescription) may help to prevent the further development of antibiotic-resistant bacteria. Research and development of more effective antibiotics are essential for improving cure rates for severe MRSA infections.
Bibliography
Alghamdi, Bandar Ali, et al. "Antimicrobial Resistance in Methicillin-Resistant Staphylococcus Aureus." Saudi Journal of Biological Sciences, vol. 30, no. 4, Apr. 2023, doi.org/10.1016/j.sjbs.2023.103604. Accessed 3 Apr. 2024.
"All You Need to Know About MRSA." Medical News Today, 15 June 2023, www.medicalnewstoday.com/articles/10634. Accessed 3 Apr. 2024.
Boyer, Anthony F., and Marin H. Kollef. "Prevention and Treatment of Methicillin-Resistant Staphylococcus aureus Colonization in the ICU: A Process of Care That Should Be Considered Mandatory." Critical Care Medicine 42.2 (2014): 477–80. Print.
Bowman, M. C., D. A. Wohl, and A. H. Kaplan. “Staphylococcal Infections.” Netter’s Internal Medicine. Ed. M. S. Runge and M. A. Greganti. 2nd ed. Philadelphia: Saunders/Elsevier, 2009. Print.
Brooks, G. F., et al., eds. Jawetz, Melnick, and Adelberg’s Medical Microbiology. 27th ed. New York: McGraw, 2016. Print.
Drebes, Julia, et al. "MRSA Infections: From Classical Treatment to Suicide Drugs." Current Medicinal Chemistry 21.15 (2014): 1809–19. Print.
"Methicillin-Resistant Staphylococcus aureus (MRSA)." Natl. Inst. of Allergy and Infectious Diseases. NIH, 22 June 2015. Web. 5 May 2016.
"Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections." Centers for Disease Control and Prevention. CDC, 1 Mar. 2016. Web. 5 May 2016.
Nandhini, Palanichamy, et al. "Recent Developments in Methicillin-Resistant Staphylococcus aureus (MRSA) Treatment: A Review." Antibiotics, vol. 11, no. 5, p. 606, 29 Apr. 2022, doi.org/10.3390/antibiotics11050606. Accessed 3 Apr. 2024.
Weston, Debbie. Fundamentals of Infection Prevention and Control: Theory and Practice. Chichester: Wiley, 2013. Print.
Yok, Q. al-, and P. Moreillon. “Staphylococcus aureus (Including Staphylococcal Toxic Shock).” Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. Ed. G. L. Mandell, J. E. Bennett, and R. Dolin. 8th ed. Philadelphia: Churchill Livingstone/Elsevier, 2015. Print.